NCT06593730View on ClinicalTrials.gov

Safety and Tolerability of the Twice Daily Intra-anal Application of NRL001 Cream for 14 Days

PHASE1CompletedINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

September 30, 2007

Conditions

Faecal Incontinence

Interventions

DRUG

NRL001 cream 0.5%w/w

DRUG

NRL001 cream 0.75%w/w

DRUG

NRL001 cream 1.0%w/w

DRUG

NRL001 cream 1.5%w/w

DRUG

NRL001 cream 2.0%w/w

DRUG

NRL001 cream 2.5%w/w

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Norgine

INDUSTRY